Colorado Blood Cancer Institute

Summary

Colorado Blood Cancer Institute is a medical facility located in Denver, Colorado. This center is recognized for care of Multiple Myeloma, Cancer, Lymphoma, Acute Myelogenous Leukemia, Acute Myeloid Leukemia and other specialties. Colorado Blood Cancer Institute is involved with conducting 294 clinical trials across 447 conditions. There are 12 research doctors associated with this hospital, such as Nicholas DiBella, Alireza Eghtedar, Michael Tees, MD, and Marcello Rotta.

Top PIs

Clinical Trials running at Colorado Blood Cancer Institute

Multiple Myeloma

Non-Hodgkin's Lymphoma

Lung Cancer

Lymphoma

Breast Cancer

Acute Myeloid Leukemia

Leukemia

Cancer

Colorectal Cancer

Acute Myelogenous Leukemia

Teclistamab + Lenalidomide

for Multiple Myeloma

This is a multicenter, randomized, open-label, Phase 3 study in participants with newly diagnosed multiple myeloma to evaluate the benefits of teclistamab in combination with lenalidomide and teclistamab alone versus lenalidomide alone as maintenance therapy after autologous stem cell transplant.

Recruiting

3 awards

Phase 3

5 criteria

Anitocabtagene Autoleucel

for Multiple Myeloma

The goal of this study (iMMagine-3) is to compare the study drug, anitocabtagene autoleucel to standard of care therapy (SOCT) in participants with relapsed/refractory multiple myeloma who have received 1 to 3 prior lines of therapy, including an anti-CD38 monoclonal antibody and an immunomodulatory drug. The primary objective of this study is to compare the efficacy of anitocabtagene autoleucel versus SOCT in participants with RRMM.

Recruiting

2 awards

Phase 3

3 criteria

Lenalidomide + Dexamethasone +/- Daratumumab

for Multiple Myeloma

This phase III trial studies how well lenalidomide and dexamethasone works with or without daratumumab in treating patients with high-risk smoldering myeloma. Drugs used in chemotherapy, such as lenalidomide and dexamethasone, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as daratumumab, may induce changes in the body's immune system and may interfere with the ability of tumor cells to grow and spread. Giving lenalidomide and dexamethasone with daratumumab may work better in treating patients with smoldering myeloma.

Recruiting

2 awards

Phase 3

12 criteria